Prolonged progression-free survival in metastatic breast cancer

被引：0
|
作者：
Mayor, Susan
机构：
来源：
BRITISH JOURNAL OF HOSPITAL MEDICINE | 2008年 / 69卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：378 / 378
页数：1
相关论文
共 50 条
  • [41] Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients
    Azzopardi, N.
    Lecomte, T.
    Ternant, D.
    Boisdron-celle, M.
    Piller, F.
    Morel, A.
    Gouilleux-gruart, V.
    Vignault, C.
    Watier, H.
    Gamelin, E.
    Paintaud, G.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 34 - 34
  • [42] Panitumumab significantly improves progression-free survival in patients with metastatic colorectal cancer
    Van Cutsem, E.
    Peeters, M.
    Siena, S.
    Humblet, Y.
    Hendisz, A.
    Neyns, B.
    Canon, J.
    Van Laethem, J.
    Maurel, J.
    Richardson, G.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 27 - 27
  • [43] Circulating tumor cells in metastatic breast cancer: Are they a strong and independent predictor of poor progression-free and overall survival?
    Wallwiener, Markus
    Schneeweiss, Andreas
    Baccelli, Irene
    Riethdorf, Sabine
    Pantel, Klaus
    Marme, Frederik
    Schott, Sarah
    Trumpp, Andreas
    Taran, Florin-Andrei
    Hahn, Markus
    Schuetz, Florian
    Mueller, Volkmar
    Rack, Brigitte Kathrin
    Sohn, Christof
    Solomayer, Erich-Franz
    Janni, Wolfgang
    Hartkopf, Andreas D.
    Fehm, Tanja N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Elevated pretreatment serum activin A and progression-free and overall survival in trastuzumab-treated metastatic breast cancer
    Zubritsky, Lindsey
    Leitzel, Kim
    Ali, Suhail M.
    Kstler, Wolfgang
    Fuchs, Eva-Maria
    Costa, Luis
    Knight, Robert D.
    Laadem, Abderrahmane
    Sherman, Matthew L.
    Lipton, Allan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (30)
  • [45] Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
    Pauline Rochefort
    Sylvie Chabaud
    Jean-Yves Pierga
    Olivier Tredan
    Etienne Brain
    François-Clément Bidard
    Camille Schiffler
    Helena Polena
    Abir Khalil-Mgharbel
    Isabelle Vilgrain
    Thomas Bachelot
    [J]. British Journal of Cancer, 2017, 116 : 356 - 361
  • [46] Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer
    Svensson, Helene
    Hatschek, Thomas
    Johansson, Hemming
    Einbeigi, Zakaria
    Brandberg, Yvonne
    [J]. MEDICAL ONCOLOGY, 2012, 29 (02) : 432 - 438
  • [47] Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
    Rochefort, Pauline
    Chabaud, Sylvie
    Pierga, Jean-Yves
    Tredan, Olivier
    Brain, Etienne
    Bidard, Francois-Clement
    Schiffler, Camille
    Polena, Helena
    Khalil-Mgharbel, Abir
    Vilgrain, Isabelle
    Bachelot, Thomas
    [J]. BRITISH JOURNAL OF CANCER, 2017, 116 (03) : 356 - 361
  • [48] Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer
    Helene Svensson
    Thomas Hatschek
    Hemming Johansson
    Zakaria Einbeigi
    Yvonne Brandberg
    [J]. Medical Oncology, 2012, 29 : 432 - 438
  • [49] Progression-free survival with regorafenib in gastric cancer
    Burki, Talha Khan
    [J]. LANCET ONCOLOGY, 2016, 17 (08): : E323 - E323
  • [50] Circadian robustness as an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC).
    Levi, Francis
    Parganiha, Arti
    Karaboue, Abdoulaye
    Innominato, Pasquale F.
    Giacchetti, Sylvie
    Garufi, Carlo
    Dispersyn, Garance
    Focan, C. N. J.
    Iacobelli, Stefano
    Bjarnason, Georg A.
    Moreau, Thierry
    Dugue, Pierre Antoine
    Waterhouse, Jim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345